A cannabidiol compound and its preparation method and use

The loading of cannabidiol by cyclodextrin metal organic framework solves the problems of low solubility and bioavailability of cannabidiol in water, and achieves its efficient dissolution and antioxidant activity. It is suitable for drugs or functional foods.

CN114681436BActive Publication Date: 2024-12-03BEIJING ZHONGKE JOINYOU BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210406536.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-18
Publication Date
2024-12-03
Estimated Expiration
2042-04-18

AI Technical Summary

Technical Problem

Due to its fat-soluble properties, cannabidiol is difficult to dissolve in water, resulting in low bioavailability. The preparation methods of the prior art are complex and costly, making it difficult to expand its application range.

Method used

Cannabidiol is loaded with cyclodextrin metal organic framework, and the interaction between phenolic hydroxyl groups and hydroxyl groups is used to form a stable binding, which improves the hydrogen donation ability and controlled release performance of cannabidiol, and combines the high specific surface area and void structure of cyclodextrin to enhance the Its dissolution and bioavailability.

Benefits of technology

It significantly improves the dissolution and antioxidant activity of cannabidiol, has stronger cytotoxicity to cancer cells, improves bioavailability, significantly improves solubility and release rate, and is suitable for drugs or functional foods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0004898509470000181
    Figure GDA0004898509470000181
  • Figure GDA0004898509470000201
    Figure GDA0004898509470000201
Patent Text Reader

Abstract

The present invention relates to a cannabidiol composite, a preparation method and use thereof, wherein the composite comprises a cyclodextrin metal organic framework and cannabidiol loaded on the cyclodextrin metal organic framework. The preparation method comprises: mixing the cyclodextrin metal organic framework and the cannabidiol solution, and then drying to obtain the composite. The cannabidiol composite provided by the present invention can load more cannabidiol, has higher cannabidiol solubility and antioxidant activity, and has stronger cytotoxicity to cancer cells. The preparation method of the present invention is simple to operate and can be promoted industrially, which is of great significance for the development of medicines or functional foods containing cannabidiol.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to preparation technology and application fields, and in particular to a cannabidiol compound and a preparation method and application thereof. Background Art

[0002] Cannabidiol comes from the annual herbaceous plant of the genus Cannabis in the Cannabaceae family. Specifically, it comes from the natural active ingredients extracted from the stems, leaves, and seeds of cannabis. It has multiple pharmacological activities, including anti-tumor, neuroprotective, metabolic and immunomodulatory, cardiovascular protection, anti-inflammatory and antioxidant, as well as liver protection and antibacterial effects. Based on the above pharmacological effects, cannabidiol can be used in a variety of fields such as medicine, food, skin care products, health products, and pet products to play its different functions.

[0003] Cannabidiol is a fat-soluble substance that is extremely difficult to dissolve in water. It usually floats on the top of the water and does not form a stable water-soluble solution. Since cannabidiol is insoluble in water, it is easily destroyed, decomposed or cleared by the liver, resulting in a reduction in the amount delivered to the subject and a greatly reduced bioavailability. In short, the wide range and excellent pharmacological properties of cannabidiol are difficult to achieve maximum bioavailability due to its special fat solubility, and its scope of use is therefore limited.

[0004] Metal-organic frameworks (MOFs) are highly ordered organic-inorganic hybrid crystalline materials formed by the coordination of metal ions and organic ligands. MOFs are widely used in various industries due to their clear structure, ultra-high specific surface area and porosity, adjustable size, and easy functionalization. In the field of biomedicine, metal-organic frameworks are also a hot material used in diagnostic preparations, nanocarriers, and drug delivery systems.

[0005] CN113101281A discloses a method for preparing a water-soluble cannabidiol inclusion complex and its application. The method comprises encapsulating cannabidiol with cyclodextrin to obtain a water-soluble cannabidiol inclusion complex. However, the method has the following problems: the solubility of cannabidiol in water is low, the inclusion rate and yield of the inclusion complex are low, and the inclusion process is complicated.

[0006] CN114073671A discloses a water-soluble cannabidiol composition, preparation, preparation method and application thereof. The method increases the solubility of cannabidiol in water by adding a nonionic surfactant and an anionic surfactant, but the preparation process is complicated and the production cost is high.

[0007] Therefore, providing a simple and effective preparation method to increase the water solubility, stability and bioavailability of cannabidiol is of great significance to expand its scope of application. Summary of the invention

[0008] In view of the above problems, the object of the present invention is to provide a cannabidiol complex and a preparation method and use thereof. Compared with the prior art, the cannabidiol complex provided by the present invention can improve the solubility of cannabidiol. The preparation method provided by the present invention is simple to operate, and the obtained cannabidiol complex can be used to prepare medicines or functional foods.

[0009] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0010] In a first aspect, the present invention provides a cannabidiol complex, comprising a cyclodextrin metal-organic framework and cannabidiol loaded on the cyclodextrin metal-organic framework.

[0011] In the present invention, cannabidiol is loaded with a cyclodextrin metal organic framework to obtain a complex of the two, wherein the cyclodextrin metal organic framework can form a stable combination with cannabidiol. On the one hand, the phenolic hydroxyl group of cannabidiol interacts with the hydroxyl group of the cyclodextrin metal organic framework to improve the hydrogen giving ability of cannabidiol, and on the other hand, the obtained complex, as a controlled release system of cannabidiol, improves the utilization rate of cannabidiol. Based on this, the complex provided by the present invention has higher antioxidant activity, has stronger cytotoxicity to cancer cells, can be used for medicines or functional foods, and can be used as an antioxidant component or anticancer component of medicines or functional foods. The complex provided by the present invention is loaded with cannabidiol by a cyclodextrin metal organic framework, and the dissolution performance of cannabidiol can be significantly enhanced by the interaction of the two, and further combined with the ultra-high specific surface area and abundant voids of the cyclodextrin metal organic framework, more action sites are provided for cannabidiol and the cyclodextrin metal organic framework, not only the dissolution of cannabidiol is improved, but also the bioavailability of cannabidiol is improved, so that cannabidiol is more easily absorbed by the human body as an antioxidant component or an anticancer component. Compared with the currently available water-soluble cannabidiol agents (for example, inclusion complexes of cannabidiol and cyclodextrin), the complex provided by the present invention has better solubility and antioxidant activity, and has stronger cytotoxicity to cancer cells. In addition, the current preparation method of water-soluble cannabidiol has the disadvantages of low solubility and yield and complex preparation process.

[0012] Preferably, the cyclodextrin in the cyclodextrin metal-organic framework includes any one of β-cyclodextrin, sulfobutyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxybutyl-β-cyclodextrin, methyl-β-cyclodextrin, dimethyl-β-cyclodextrin or γ-cyclodextrin, or a combination of at least two of them, wherein typical but non-limiting combinations include a combination of β-cyclodextrin and methyl-β-cyclodextrin, a combination of methyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin, or a combination of hydroxybutyl-β-cyclodextrin and sulfobutyl-β-cyclodextrin, preferably hydroxypropyl-β-cyclodextrin and / or dimethyl-β-cyclodextrin.

[0013] The preferred cyclodextrin of the present invention is hydroxypropyl-β-cyclodextrin and / or dimethyl-β-cyclodextrin because hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin have better water solubility and stronger binding ability with cannabidiol.

[0014] Preferably, the coordinated metal ions in the cyclodextrin metal organic framework include Al 3+ 、Co 2+ , Fe 3+ , Pt 2+ Cr 3+ 、Zn 2+ 、Zr 4+ , Cu 2+ 、Ni 2+ or K + Any one or a combination of at least two of the following, wherein a typical but non-limiting combination includes Cu 2+ and Ni 2+ The combination of Ni 2+ and Al 3+ Combination or Fe 3+ and Zn 2+ A combination of Al 3+ and / or K + .

[0015] The preferred metal ions of the present invention include Al 3+ and / or K + , because Al 3+ and K + The cost is low and it is readily available, and the yield of the prepared cyclodextrin metal organic framework is high.

[0016] Preferably, the mass percentage of cannabidiol in the composite is 1-20%, for example, it can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%, but is not limited to the listed values, and other unlisted values ​​within the numerical range are also applicable.

[0017] Preferably, the molar ratio of cyclodextrin metal organic framework to cannabidiol in the complex is 1:(0.1-2), for example, it can be 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9 or 1:2, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0018] The present invention preferably controls the molar ratio of cyclodextrin metal organic framework to cannabidiol within a specific range, which can reduce costs and control the reaction process.

[0019] Preferably, the crystal size of the cyclodextrin metal organic framework is 4-10 μm, for example, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm or 10 μm, but is not limited to the listed values, and other unlisted values ​​within the numerical range are also applicable.

[0020] In a second aspect, the present invention provides a method for preparing a cannabidiol complex as described in the first aspect of the present invention, the preparation method comprising: mixing a cyclodextrin metal organic framework and a cannabidiol solution, and then drying to obtain the cannabidiol complex.

[0021] The present invention mixes a cyclodextrin metal-organic framework and a cannabidiol solution to fully load cannabidiol on the cyclodextrin metal-organic framework carrier, and further obtains a cannabidiol complex by drying. The preparation method provided by the present invention is simple to operate, and can achieve full loading of cannabidiol on the cyclodextrin metal-organic framework. The cannabidiol in the obtained complex has good solubility and antioxidant activity, and has high cytotoxicity to cancer cells.

[0022] Preferably, the molar ratio of the cyclodextrin metal organic framework to cannabidiol in the cannabidiol solution is 1:(0.5-5), for example, it can be 1:0.5, 1:0.6, 1:0.8, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.6, 1:3.8, 1:4, 1:4.2, 1:4.4, 1:4.6, 1:4.8 or 1:5, but is not limited to the listed values, and other unlisted values ​​within the numerical range are also applicable, preferably 1:(3-5).

[0023] Preferably, the mass ratio of cannabidiol to solvent in the cannabidiol solution is 1:(10-50), for example, it can be 1:10, 1:12, 1:15, 1:18, 1:20, 1:22, 1:25, 1:28, 1:30, 1:32, 1:35, 1:38, 1:40, 1:42, 1:45, 1:48 or 1:50, but is not limited to the listed values, and other unlisted values ​​within the numerical range are also applicable.

[0024] Preferably, the solvent comprises ethanol.

[0025] Preferably, the mixing method includes any one of stirring treatment, microwave treatment, ultrasonic treatment or high-pressure homogenization treatment.

[0026] In the present invention, if the mixing method adopts stirring treatment, the temperature of the stirring treatment is 20-70°C, the speed is 50-200r / min, and the time is 2-8h; if the mixing method adopts microwave treatment, the frequency of the microwave treatment is 1000-3000MHz, the power is 500-1000W, and the time is 5-20min; if the mixing method adopts ultrasonic treatment, the power of the ultrasonic treatment is 2000-5000W, the temperature is 20-75°C, and the time is 0.5-8h; if the mixing method adopts high-pressure homogenization treatment, the pressure of the high-pressure homogenization treatment is 20-70MPa, the temperature is 20-50°C, the time is 10-50min, and the number of treatments is 1-5 times.

[0027] Preferably, the drying method includes any one of freeze drying, spray drying or vacuum drying.

[0028] In the present invention, if freeze drying is used as the drying method, the freeze drying time is 36-48 hours, the vacuum degree is -(0.05-0.07) MPa, and the temperature is -(10-30)°C; if spray drying is used as the drying method, the inlet air temperature of the spray drying is 100-200°C, and the outlet air temperature is 50-100°C; if vacuum drying is used as the drying method, the vacuum drying time is 48-96 hours, the vacuum degree is -(0.07-0.09) MPa, and the temperature is 30-60°C.

[0029] Preferably, the method for preparing the cyclodextrin metal organic framework comprises the following steps:

[0030] (1) mixing cyclodextrin and a metal compound, then ultrasonically obtaining a mixed solution, and stirring the mixed solution to obtain a pretreatment solution;

[0031] (2) mixing the pretreatment solution obtained in step (1) and a cross-linking agent, and then reacting to obtain a reaction solution;

[0032] (3) The reaction solution obtained in step (2) is cooled, and then solid-liquid separation, washing and drying are performed in sequence to obtain the cyclodextrin metal organic framework.

[0033] The present invention has no specific limitation on the method of solid-liquid separation, which can be any method known to those skilled in the art for solid-liquid separation, such as centrifugation or filtration.

[0034] The washing in the present invention includes washing with ethanol and methanol 2 to 3 times each to remove impurities.

[0035] Preferably, the molar ratio of the cyclodextrin in step (1) to the metal ion in the metal compound is 1:(0.05-0.2), for example, it can be 1:0.05, 1:0.06, 1:0.08, 1:0.1, 1:0.12, 1:0.14, 1:0.16, 1:0.18 or 1:0.2, but is not limited to the listed values. Other values ​​not listed within the numerical range are also applicable, preferably 1:0.1.

[0036] The present invention preferably controls the molar ratio of cyclodextrin to the metal ion in the metal compound within a specific range, which can reduce costs and control the reaction process.

[0037] Preferably, an alkaline solution is also added to the mixing in step (1).

[0038] Preferably, the mass ratio of the sum of the masses of the cyclodextrin and the metal compound to the mass ratio of the alkaline solution in step (1) is 1:(5-40), for example, it can be 1:5, 1:6, 1:8, 1:10, 1:12, 1:15, 1:18, 1:20, 1:22, 1:25, 1:28, 1:30, 1:32, 1:35, 1:38 or 1:40, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0039] Preferably, the pH of the alkaline solution in step (1) is 8-11, for example, 8, 8.5, 9, 9.5, 10, 10.5 or 11, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable, preferably 9-10.

[0040] The present invention preferably controls the pH of the alkaline solution within a specific range, which can promote the reaction and control the direction of the reaction.

[0041] The present invention has no particular limitation on the alkaline solution, and the alkaline solution may be, for example, a sodium hydroxide solution, a potassium hydroxide solution or an aluminum hydroxide solution.

[0042] Preferably, the ultrasonic time in step (1) is 0.2-1h, for example, it can be 0.2h, 0.3h, 0.4h, 0.5h, 0.6h, 0.7h, 0.8h, 0.9h or 1h, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0043] Preferably, the mixed solution in step (1) is stirred after adding the alcohol additive.

[0044] Preferably, the alcohol additive in step (1) comprises methanol.

[0045] Preferably, the mass ratio of the mixed solution to the alcohol additive in step (1) is 1:(0.5-5), for example, it can be 1:0.5, 1:0.6, 1:0.8, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.6, 1:3.8, 1:4, 1:4.2, 1:4.4, 1:4.6, 1:4.8 or 1:5, but is not limited to the listed values, and other unlisted values ​​within the numerical range are also applicable, preferably 1:1.

[0046] Preferably, the stirring time in step (1) is 0.2-1 h, for example, 0.2 h, 0.3 h, 0.4 h, 0.5 h, 0.6 h, 0.7 h, 0.8 h, 0.9 h or 1 h, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0047] Preferably, the cross-linking agent in step (2) comprises polyethylene glycol.

[0048] In the present invention, when the pretreatment solution is clarified, a cross-linking agent is added.

[0049] Preferably, the polyethylene glycol in step (2) includes any one of polyethylene glycol 4000, polyethylene glycol 8000, polyethylene glycol 12000, polyethylene glycol 16000 or polyethylene glycol 20000.

[0050] Preferably, the mass ratio of the cross-linking agent to the pretreatment solution in step (2) is (0.001-0.05):1, for example, it can be 0.001:1, 0.002:1, 0.005:1, 0.008:1, 0.01:1, 0.02:1, 0.03:1, 0.04:1 or 0.05:1, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0051] Preferably, the reaction time of step (2) is 0.2-1 h, for example, 0.2 h, 0.3 h, 0.4 h, 0.5 h, 0.6 h, 0.7 h, 0.8 h, 0.9 h or 1 h, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0052] Preferably, the temperature of the cooling treatment in step (3) is 1-20°C, for example, it can be 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 12°C, 14°C, 16°C, 18°C ​​or 20°C, but is not limited to the listed values, and other unlisted values ​​within the numerical range are also applicable.

[0053] In the present invention, when the reaction solution is clarified, a cooling treatment is performed.

[0054] Preferably, the drying time in step (3) is 1-12 h, for example, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 11 h or 12 h, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0055] As a preferred technical solution of the second aspect of the present invention, the preparation method comprises the following steps:

[0056] (1) Mixing cyclodextrin and the metal compound in an alkaline solution at a mass ratio of the sum of the mass of cyclodextrin and the metal compound to the mass ratio of the alkaline solution is 1:(5-40), then ultrasonicating for 0.2-1h to obtain a mixed solution, adding methanol to the mixed solution and stirring for 0.2-1h to obtain a pretreatment solution; the pH of the alkaline solution is 8-11, the molar ratio of the cyclodextrin to the metal ion in the metal compound is 1:(0.05-0.2), and the mass ratio of the mixed solution to methanol is 1:(0.5-5);

[0057] (2) mixing the pretreatment solution obtained in step (1) and polyethylene glycol, and reacting for 0.2-1h to obtain a reaction solution, wherein the mass ratio of the polyethylene glycol to the pretreatment solution is (0.001-0.05):1;

[0058] (3) cooling the reaction solution obtained in step (2) at 1-20° C., then performing solid-liquid separation and washing in sequence, and then drying for 1-12 hours to obtain the cyclodextrin metal organic framework;

[0059] (4) mixing the cyclodextrin metal organic framework obtained in step (3) and the cannabidiol solution, and then drying to obtain the cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:(0.5-5), the mass ratio of cannabidiol in the cannabidiol solution to the solvent is 1:(10-50), and the solvent includes ethanol.

[0060] In a third aspect, the present invention provides a use of a cannabidiol complex as described in the first aspect of the present invention, wherein the complex is used to prepare medicines or functional foods.

[0061] The cannabidiol complex provided by the present invention has high cannabidiol solubility and good bioavailability. Cannabidiol has nerve protection, anti-epileptic, anti-spasmodic, antioxidant, anti-cancer and whitening effects, especially has high antioxidant activity and high cytotoxicity to cancer cells. It can be used to prepare medicines or functional foods and used as an antioxidant or anti-cancer ingredient.

[0062] In the present invention, the dosage form of the medicine includes any one of granules, tablets, capsules, pills, powders or pastes. The dosage form of the functional food in the present invention includes any one of solid granule drinks or tablets. The preparation method of the functional food in the present invention includes: mixing the cannabidiol complex and auxiliary materials to prepare a solid granule drink or press it into tablets, and the auxiliary materials include but are not limited to povidone, stearic acid, magnesium stearate, polyethylene glycol, titanium dioxide, butylated hydroxyanisole, talc, micro-powder silica gel, dextrin, starch or lactose, etc.

[0063] Preferably, in the medicine or functional food, the mass percentage of the complex is 0.1-20%, for example, it can be 0.1%, 0.5%, 0.8%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%, but is not limited to the listed values, and other values ​​not listed within the numerical range are also applicable.

[0064] Compared with the prior art, the present invention has the following beneficial effects:

[0065] (1) The cannabidiol complex provided by the present invention can load more cannabidiol, effectively improve the solubility of cannabidiol, and thus have a higher bioavailability and be more easily absorbed by the human body. In an in vitro dissolution test, the solubility of cannabidiol is above 667 μg / mL, and reaches above 760 μg / mL under optimal conditions. The release rate of cannabidiol is above 86.7%, and reaches above 90.9% under optimal conditions.

[0066] (2) The cannabidiol complex provided by the present invention has high antioxidant activity and strong cytotoxicity to cancer cells. Taking the DPPH and ABTS free radical scavenging test as an example, the EC 50 The EC of ABTS removal can reach below 80.2μg / mL, and under optimal conditions can reach below 68.5μg / mL. 50 It can reach below 14.5μg / mL, and can reach below 10.2μg / mL under optimal conditions; in the cytotoxicity test, it can inhibit cell viability to below 28.3%, and reach below 16.9% under optimal conditions.

[0067] (3) The preparation method of the cannabidiol complex provided by the present invention is simple to operate, can increase the loading amount of cannabidiol, and can be promoted industrially.

[0068] (3) The cannabidiol complex provided by the present invention can be used in medicines or functional foods, especially as an antioxidant component or anti-cancer component in medicines or functional foods, and has good neuroprotective, anti-epileptic, antioxidant, anti-cancer, anti-spasmodic and whitening effects. DETAILED DESCRIPTION

[0069] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0070] Example 1

[0071] This embodiment provides a method for preparing a cannabidiol compound, the preparation method comprising the following steps:

[0072] (1) mixing hydroxypropyl-β-cyclodextrin, dimethyl-β-cyclodextrin and KCl in a potassium hydroxide solution with a pH of 9, and then ultrasonicating for 0.6 h to obtain a mixed solution, adding methanol to the mixed solution, and stirring at 60° C. for 0.6 h to obtain a pretreatment solution; the molar ratio of the hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin is 1:1, the ratio of the sum of the molar amounts of the hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin to the molar amount of K ions is 1:0.125, and the mass ratio of the mixed solution to methanol is 1:2.75; the mass ratio of the sum of the masses of the hydroxypropyl-β-cyclodextrin, dimethyl-β-cyclodextrin and KCl to the potassium hydroxide solution is 1:22;

[0073] (2) mixing the pretreatment solution obtained in step (1) with polyethylene glycol 20000, wherein the mass ratio of polyethylene glycol 20000 to the pretreatment solution is 0.03:1, and reacting for 0.6 h to obtain a reaction solution;

[0074] (3) cooling the reaction solution obtained in step (2) at 10° C. for 2 h, centrifuging it, washing it twice with anhydrous ethanol and methanol respectively, and then drying it for 6 h to obtain the cyclodextrin metal organic framework;

[0075] (4) dissolving cannabidiol in ethanol to obtain a cannabidiol solution, stirring the cyclodextrin metal organic framework and cannabidiol solution obtained in step (3) at 30° C. for 4 hours at a stirring rate of 100 r / min, and then freeze-drying at -10° C. and -0.06 MPa for 36 hours to obtain the cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:2.75, and the mass ratio of cannabidiol to ethanol in the cannabidiol solution is 1:30.

[0076] This embodiment also provides a cannabidiol complex, in which the mass percentage of cannabidiol in the complex is 17.2%, the molar ratio of cyclodextrin metal organic framework to cannabidiol is 1:0.95, and the crystal size of the cyclodextrin metal organic framework is 8.5 μm. In parts by weight, 5 parts of the complex, 5 parts of povidone, 5 parts of stearic acid, 10 parts of magnesium stearate, 5 parts of polyethylene glycol, 10 parts of titanium dioxide, 5 parts of butylated hydroxyanisole, 5 parts of talc, 5 parts of micro powder silica gel, 20 parts of starch, and 30 parts of lactose are taken, and after pressing, a cannabidiol drug is obtained, which is a tablet, and the mass percentage of the complex is 5%.

[0077] Example 2

[0078] This embodiment provides a method for preparing a cannabidiol compound, the preparation method comprising the following steps:

[0079] (1) mixing hydroxypropyl-β-cyclodextrin and KCl in a potassium hydroxide solution with a pH value of 8, and then ultrasonicating for 0.2 h to obtain a mixed solution, adding methanol to the mixed solution, and stirring at 60° C. for 1 h to obtain a pretreatment solution; the molar ratio of the hydroxypropyl-β-cyclodextrin to the K ion is 1:0.05, and the mass ratio of the mixed solution to methanol is 1:5; the mass ratio of the sum of the mass of the hydroxypropyl-β-cyclodextrin and KCl to the potassium hydroxide solution is 1:40;

[0080] (2) mixing the pretreatment solution obtained in step (1) with polyethylene glycol 12000, wherein the mass ratio of polyethylene glycol 12000 to the pretreatment solution is 0.001:1, and reacting for 0.2 h to obtain a reaction solution;

[0081] (3) cooling the reaction solution obtained in step (2) at 20° C. for 2 h, then centrifuging, washing with anhydrous ethanol and methanol twice each, and then drying for 12 h to obtain the cyclodextrin metal organic framework;

[0082] (4) dissolving cannabidiol in ethanol to obtain a cannabidiol solution, stirring the cyclodextrin metal organic framework and cannabidiol solution obtained in step (3) at 30° C. for 4 hours at a stirring rate of 100 r / min, and then freeze-drying at -10° C. and -0.06 MPa for 36 hours to obtain the cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:1.5, and the mass ratio of cannabidiol to ethanol in the cannabidiol solution is 1:50.

[0083] This embodiment also provides a cannabidiol complex, wherein the mass percentage of cannabidiol in the complex is 8.9%, the molar ratio of cyclodextrin metal organic framework to cannabidiol is 1:1.15, and the crystal size of the cyclodextrin metal organic framework is 6.3 μm. By weight, 5 parts of the complex, 4 parts of povidone, 10 parts of maltodextrin, 10 parts of polydextrose, 5 parts of guar gum, 3 parts of lactic acid, 3 parts of sodium tripolyphosphate, 3 parts of acesulfame potassium, 5 parts of food coloring, 5 parts of sodium carboxymethyl cellulose, 5 parts of citric acid, 5 parts of sodium citrate, and 5 parts of edible flavors are mixed to obtain a solid cannabidiol beverage, wherein the mass percentage of the complex is 7%.

[0084] Example 3

[0085] This embodiment provides a method for preparing a cannabidiol compound, the preparation method comprising the following steps:

[0086] (1) mixing dimethyl-β-cyclodextrin and AlCl3 in an aluminum hydroxide solution with a pH value of 11, and then ultrasonicating for 0.05 h to obtain a mixed solution, adding methanol to the mixed solution, and stirring at 60° C. for 0.2 h to obtain a pretreatment solution; the molar ratio of dimethyl-β-cyclodextrin to Al ions is 1:0.2, and the mass ratio of the mixed solution to methanol is 1:0.5; the mass ratio of the sum of the mass of dimethyl-β-cyclodextrin and AlCl3 to the aluminum hydroxide solution is 1:5;

[0087] (2) mixing the pretreatment solution obtained in step (1) with polyethylene glycol 18000, wherein the mass ratio of polyethylene glycol 18000 to the pretreatment solution is 0.05:1, and reacting for 1 hour to obtain a reaction solution;

[0088] (3) cooling the reaction solution obtained in step (2) at 1° C. for 2 h, then centrifuging, washing with anhydrous ethanol and methanol twice each, and then drying for 1 h to obtain the cyclodextrin metal organic framework;

[0089] (4) dissolving cannabidiol in ethanol to obtain a cannabidiol solution, stirring the cyclodextrin metal organic framework and cannabidiol solution obtained in step (3) at 30° C. for 4 hours at a stirring rate of 100 r / min, and then freeze-drying at -10° C. and -0.06 MPa for 36 hours to obtain the cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:5, and the mass ratio of cannabidiol to ethanol in the cannabidiol solution is 1:10.

[0090] This embodiment also provides a cannabidiol complex, in which the mass percentage of cannabidiol in the complex is 19.1%, the molar ratio of cyclodextrin metal organic framework to cannabidiol is 1:1, and the crystal size of the cyclodextrin metal organic framework is 7.2 μm. In parts by weight, 5 parts of the complex, 6 parts of povidone, 4 parts of stearic acid, 5 parts of magnesium stearate, 10 parts of polyethylene glycol, 20 parts of titanium dioxide, 5 parts of butylated hydroxyanisole, 5 parts of talc, 10 parts of micro powder silica gel, 30 parts of starch, and 30 parts of lactose are taken, and after pressing, a cannabidiol drug is obtained, which is a tablet, and the mass percentage of the complex is 4%.

[0091] Example 4

[0092] This embodiment provides a method for preparing a cannabidiol compound, the preparation method comprising the following steps:

[0093] (1) Accurately weigh 10 g of hydroxypropyl-β-cyclodextrin and 1 g of CrCl3, mix them in 50 mL of a sodium hydroxide solution with a pH of 9, and then ultrasonicate for 0.6 h to obtain a mixed solution, add 100 mL of methanol to the mixed solution, and stir at 60° C. for 0.4 h to obtain a pretreatment solution; the molar ratio of the cyclodextrin to the metal ion in the metal compound is 1:0.12, and the mass ratio of the mixed solution to methanol is 1:3; the mass ratio of the sum of the mass of the cyclodextrin and the metal compound to the sodium hydroxide solution is 1:30;

[0094] (2) mixing the pretreatment solution obtained in step (1) with 100 mg of polyethylene glycol 20000, wherein the mass ratio of the polyethylene glycol 20000 to the pretreatment solution is 0.04:1, and reacting for 0.2 h to obtain a reaction solution;

[0095] (3) cooling the reaction solution obtained in step (2) at 15° C. for 2 h, then centrifuging, washing with anhydrous ethanol and methanol twice each, and then drying for 6 h to obtain the cyclodextrin metal organic framework;

[0096] (4) 6 g of cannabidiol was dissolved in 200 mL of ethanol to obtain a cannabidiol solution, and 2 g of the cyclodextrin metal organic framework and the cannabidiol solution obtained in step (3) were subjected to microwave treatment at a frequency of 1000 MHz, a power of 500 W, and a time of 10 min, and then spray dried at an inlet air temperature of 100° C. and an outlet air temperature of 100° C. to obtain a cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution was 1:4, and the mass ratio of cannabidiol to ethanol in the cannabidiol solution was 1:35.

[0097] Example 5

[0098] This embodiment provides a method for preparing a cannabidiol compound, the preparation method comprising the following steps:

[0099] (1) Accurately weigh 10 g of hydroxypropyl-β-cyclodextrin and 1 g of ZnCl2 and mix them in 50 mL of sodium hydroxide solution with a pH of 8, then ultrasonicate for 0.2 h to obtain a mixed solution, add 25 mL of methanol to the mixed solution and stir at 60° C. for 0.8 h to obtain a pretreatment solution; the molar ratio of the hydroxypropyl-β-cyclodextrin to the Zn ion is 1:0.2, and the mass ratio of the mixed solution to methanol is 1:2.5; the mass ratio of the sum of the mass of the hydroxypropyl-β-cyclodextrin and ZnCl2 to the sodium hydroxide solution is 1:25;

[0100] (2) mixing the pretreatment solution obtained in step (1) with 75 mg of polyethylene glycol 16000, wherein the mass ratio of polyethylene glycol 16000 to the pretreatment solution is 0.035:1, and reacting for 0.8 h to obtain a reaction solution;

[0101] (3) cooling the reaction solution obtained in step (2) at 10° C. for 2 h, then centrifuging, washing with anhydrous ethanol and methanol twice each, and then drying for 2 h to obtain the cyclodextrin metal organic framework;

[0102] (4) 10 g of cannabidiol was dissolved in 100 mL of ethanol to obtain a cannabidiol solution, and 2 g of the cyclodextrin metal organic framework and the cannabidiol solution obtained in step (3) were subjected to microwave treatment for 10 min at a frequency of 2000 MHz and a power of 1000 W, and then freeze-dried at -10°C and -0.06 MPa for 36 h to obtain a cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution was 1:3.5, and the mass ratio of cannabidiol to ethanol in the cannabidiol solution was 1:40.

[0103] Example 6

[0104] This embodiment provides a method for preparing a cannabidiol compound, the preparation method comprising the following steps:

[0105] (1) Accurately weighing 10 g of sulfobutyl-β-cyclodextrin and 0.5 g of NiCl2, mixing them in 50 mL of a sodium hydroxide solution with a pH of 9, and then ultrasonicating them for 0.2 h to obtain a mixed solution, adding 125 mL of methanol to the mixed solution and stirring them at 60° C. for 0.5 h to obtain a pretreatment solution; the molar ratio of the sulfobutyl-β-cyclodextrin to the Ni ion is 1:0.2, and the mass ratio of the mixed solution to the methanol is 1:3.5; the mass ratio of the sum of the mass of the sulfobutyl-β-cyclodextrin and NiCl2 to the sodium hydroxide solution is 1:25;

[0106] (2) mixing the pretreatment solution obtained in step (1) with 50 mg of polyethylene glycol 12000, wherein the mass ratio of polyethylene glycol 12000 to the pretreatment solution is 0.04:1, and reacting for 1 hour to obtain a reaction solution;

[0107] (3) cooling the reaction solution obtained in step (2) at 8° C. for 2 h, then centrifuging, washing with anhydrous ethanol and methanol twice each, and then drying for 12 h to obtain the cyclodextrin metal organic framework;

[0108] (4) 10 g of cannabidiol was dissolved in 100 mL of ethanol to obtain a cannabidiol solution, and 2 g of the cyclodextrin metal organic framework and the cannabidiol solution obtained in step (3) were subjected to high-pressure homogenization at a pressure of 20 MPa, a temperature of 30° C., and a time of 20 min. The treatment was repeated 3 times, and then freeze-dried at -10° C. and -0.06 MPa for 36 h to obtain the cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution was 1:4, and the mass ratio of cannabidiol to ethanol in the cannabidiol solution was 1:30.

[0109] Example 7

[0110] This embodiment provides a method for preparing a cannabidiol complex, the preparation method differing from that of embodiment 1 only in that dimethyl-β-cyclodextrin is not added, and the molar amount of hydroxypropyl-β-cyclodextrin is adjusted to be equal to the sum of the molar amounts of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin in embodiment 1.

[0111] Example 8

[0112] This embodiment provides a method for preparing a cannabidiol complex, which is different from that of Example 1 only in that hydroxypropyl-β-cyclodextrin is not added, and the molar amount of dimethyl-β-cyclodextrin is adjusted to be equal to the sum of the molar amounts of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin in Example 1.

[0113] Example 9

[0114] This embodiment provides a method for preparing a cannabidiol complex. The difference between the preparation method and Example 1 is that KCl is replaced by CrCl3, and the molar amount of CrCl3 is the same as the molar amount of KCl in Example 1.

[0115] Example 10

[0116] This embodiment provides a method for preparing a cannabidiol complex, the preparation method being different from that of Example 1 only in that the ratio of the sum of the molar amounts of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin to the molar amount of K ions in KCl is 1:0.01.

[0117] Embodiment 11

[0118] This embodiment provides a method for preparing a cannabidiol complex, and the preparation method is different from that of Example 1 only in that the ratio of the sum of the molar amounts of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin to the molar amount of K ions in KCl is 1:1.

[0119] Example 12

[0120] This embodiment provides a method for preparing a cannabidiol complex, and the preparation method is different from that of Example 1 only in that the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:0.3.

[0121] Example 13

[0122] This embodiment provides a method for preparing a cannabidiol complex, and the preparation method is different from that of Example 1 only in that the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:10.

[0123] Comparative Example 1

[0124] This comparison provides a cannabidiol medicament, and its preparation method is: hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin are dissolved in dimethyl sulfoxide-water solution, the volume ratio of dimethyl sulfoxide to water in the dimethyl sulfoxide-water solution is 1: 1, the sum of the mass of the hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin and the mass ratio of the dimethyl sulfoxide-water solution is 1: 22, and then a cannabidiol solution is added, and the mass ratio of cannabidiol to ethanol in the cannabidiol solution is 1: 30, and then the reaction is stirred at 2500rpm at 20°C for 1h, and then the undissolved solids are removed by microporous membrane filtration, and the filtrate is vacuum dried at 100Pa for 12h to obtain a white powder. The dosage of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin and the dosage of cannabidiol described in this comparative example are the same as those in Example 1.

[0125] Comparative Example 2

[0126] This comparative example provides a cannabidiol agent, which is a commercially available cannabidiol drug.

[0127] (1) Free radical scavenging test:

[0128] The scavenging ability of the composites in Examples 1-13 and the cannabidiol agents in Comparative Examples 1-2 on DPPH (1,1-diphenyl-2-trinitrophenylhydrazine) and ABTS (2,2'-azobis-3-ethylbenzothiazoline-6-sulfonic acid) free radicals was investigated. The half effective concentration (EC 50 ) as shown in Table 1.

[0129] Test method:

[0130] ① DPPH free radical scavenging: Take 2 mL of the first test solution of different concentrations (4 mM, 8 mM, 12 mM, 16 mM, 20 mM) (the first test solution is the methanol solution of the complex in Example 1-13 and the methanol solution of the cannabidiol agent in Comparative Example 1-2), add 2 mL of 0.2 mM DPPH solution prepared with anhydrous methanol, mix well and place in a dark room for about 30 minutes, and measure the absorbance A of the sample at a wavelength of 517 nm. 样品 Then, 2 mL of methanol was used to replace the first test solution, and 2 mL of the DPPH solution was added. After being fully mixed, the mixture was placed in a dark room for about 30 minutes, and the absorbance of the blank solution was measured at a wavelength of 517 nm. 空白 Then, take the above first test solution of different concentrations, add 2 mL of anhydrous methanol, mix thoroughly and place in a dark room for about 30 minutes, and measure the absorbance A of the drug solution itself at a wavelength of 517 nm. 对照 .

[0131] The calculation formula of clearance rate SA (%) is as follows:

[0132]

[0133] ②ABTS free radical scavenging: Take ABTS10mg, potassium persulfate K2S2O8 2.9mg dissolved in 10mL of 0.01mol / L sodium phosphate buffer, store at 25℃ in dark for 15h, and set aside. Take 2.5mL ABTS solution, add 20mL 0.01mol / L sodium phosphate buffer, dilute with distilled water, so that the absorbance at 734nm is 0.7, and obtain ABTS analysis solution. Take 1mL of the second test solution of different concentrations (0.5mM, 1mM, 2mM, 4mM, 8mM) (the second test solution is respectively the methanol solution of the complex in Example 1-13 and the methanol solution of the cannabidiol agent in Comparative Example 1-2), add 2mL of the above ABTS analysis solution to the test tube, and measure A at 734nm wavelength after 10min. 样品 ; Replace ABTS analytical solution with 2 mL of distilled water to obtain A 对照 ; Replace the second test solution with 1 mL of distilled water to obtain A 空白 . The clearance formula is as above.

[0134] The half effective concentration EC 50 The concentration of cannabidiol when the clearance rate reaches 50%.

[0135] (2) In vitro dissolution test of cannabidiol

[0136] The in vitro dissolution effects of the complexes in Examples 1-13 and the cannabidiol agents in Comparative Examples 1-2 on cannabidiol were investigated.

[0137] Test method:

[0138] Take excess sample powders (the samples are the composites in Examples 1-13 and the cannabidiol agents in Comparative Examples 1-2, respectively) and dissolve them in a conical flask containing 100 mL of deionized water, place them on a magnetic stirrer and stir, control the speed at 100 rpm, and control the temperature at 37°C. Take 1 mL of the solution at 5 min, 10 min, 15 min, 20 min, 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 360 min, 480 min, 720 min, and 1440 min, respectively, and add 1 mL of deionized water at the same time. After the liquid is taken out and passed through the membrane, the solubility of cannabidiol is detected by HPLC. The results are shown in Table 1.

[0139] (3) Cytotoxicity test

[0140] The cytotoxicity of the complex in Example 1-13 and the cannabidiol agent in Comparative Example 1-2 on the liver cancer cell line HepG2 was examined.

[0141] Test method:

[0142] The cytotoxicity of the samples to the hepatoma cell line HepG2 was determined by MTT colorimetry. HepG2 cells were cultured in high-glucose DMEM medium containing 10% fetal bovine serum. The culture conditions were 37°C and the volume concentration of CO2 was 5%. After culturing for 2 days, the cells were inoculated with a concentration of 4×10 4 96-well plates with 10 cells / ml. After 1 day, 100 μL of new culture medium containing samples (the samples are the complexes in Examples 1-13 and the cannabidiol agents in Comparative Examples 1-2, respectively) was added and cultured for another 24 hours. Then 20 μL of MTT (5 mg / ml) was added and cultured for 3 hours. Subsequently, all the culture medium was aspirated and 150 μL of DMSO solution was added to dissolve the formazan precipitate formed. The microplate reader collected the absorbance at a wavelength of 570 nm and calculated the cell viability. When the sample concentration was 50 μg / mL, the obtained cell viability was as shown in Table 1.

[0143] Table 1

[0144]

[0145] From Table 1, we can see the following points:

[0146] (1) From the data of Examples 1-13, it can be seen that the cannabidiol complex provided by the present invention has high antioxidant activity and strong cytotoxicity to cancer cells. Taking the DPPH and ABTS free radical scavenging tests as an example, the EC 50 The EC of ABTS removal can reach below 80.2μg / mL, and under optimal conditions can reach below 68.5μg / mL. 50 It can reach below 14.5μg / mL, and can reach below 10.2μg / mL under optimal conditions; in the cytotoxicity test, it can inhibit cell viability to below 28.3%, and reach below 16.9% under optimal conditions.

[0147] It can also be seen from the data of Examples 1-13 that the cannabidiol complex provided by the present invention has a high solubility, the solubility of cannabidiol is above 667 μg / mL, and reaches above 760 μg / mL under optimal conditions, and the release rate of cannabidiol is above 86.7%, and reaches above 90.9% under optimal conditions.

[0148] (2) Comprehensive comparison of the data of Example 1 and Examples 7-8 shows that the cyclodextrin in Example 1 is hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin. Compared with the cyclodextrin in Example 7 which is only hydroxypropyl-β-cyclodextrin and the cyclodextrin in Example 8 which is only dimethyl-β-cyclodextrin, the EC value of DPPH in Example 1 is 50 , EC of ABTS50 and cell viability are lower than those in Example 7 and Example 8, while the solubility and release rate of cannabidiol are higher than those in Example 7 and Example 8, which indicates that the preferred cyclodextrin of the present invention is a combination of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin, which can improve the antioxidant activity, cytotoxicity and leachability of the complex.

[0149] (3) Comprehensive comparison of the data of Example 1 and Example 9 shows that the difference between Example 9 and Example 1 is that the KCl in Example 1 is replaced by CrCl3, and the EC value of DPPH in Example 1 is 50 , EC of ABTS 50 The cell viability and solubility of cannabidiol were lower than those in Example 9, and the release rate of cannabidiol was higher than those in Example 9, which shows that the preferred coordinated metal ion in the cyclodextrin metal organic framework of the present invention is K + , which can improve the antioxidant activity, cytotoxicity and leaching properties of the complex.

[0150] (4) Comprehensive comparison of the data of Example 1 and Examples 10-11 shows that the ratio of the sum of the molar amounts of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin to the molar amount of K ions in KCl in Example 1 is 1:0.125, compared with 1:0.01 and 1:1 in Examples 10 and 11, respectively. The EC of DPPH in Example 1 is 50 , EC of ABTS 50 and cell viability are lower than those in Example 10 and Example 11, while the solubility and release rate of cannabidiol are higher than those in Example 10 and Example 11, which indicates that the present invention preferably controls the molar ratio of cyclodextrin to metal ions in the metal compound, which can improve the antioxidant activity, cytotoxicity and leaching property of the complex.

[0151] (5) Comprehensive comparison of the data of Example 1 and Examples 12-13 shows that the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution in Example 1 is 1:2.75, compared with 1:0.3 and 1:10 in Examples 12 and 13, respectively. The EC of Example 1 for DPPH is 50 , EC of ABTS 50 and cell viability are lower than those in Example 12 and Example 13, and the solubility and release rate of cannabidiol are higher than those in Example 12 and Example 13, which shows that the present invention preferably controls the molar ratio of cyclodextrin metal organic framework to cannabidiol in the cannabidiol solution, which can improve the antioxidant activity, cytotoxicity and leachability of the complex.

[0152] (7) Comprehensive comparison of the data of Example 1 and Comparative Examples 1-2 shows that the cannabidiol agent in Comparative Example 1 is an inclusion compound of cannabidiol and cyclodextrin, and the cannabidiol agent in Comparative Example 2 is commercially available cannabidiol. The EC value of DPPH in Example 1 is 50 , EC of ABTS 50 The solubility and release rate of cannabidiol are higher than those of comparative examples 1 and 2, which indicates that the present invention loads cannabidiol through a cyclodextrin metal-organic framework, and the obtained complex has high antioxidant activity, cytotoxicity and leachability.

[0153] In summary, the cannabidiol complex provided by the present invention has high antioxidant activity, strong cytotoxicity to cancer cells, and can effectively improve the solubility of cannabidiol, thereby having high bioavailability and being more easily absorbed by the human body. The complex can be used in medicines or functional foods, especially as an antioxidant component or anti-cancer component in medicines or functional foods.

[0154] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A cannabidiol compound, characterized in that The complex includes a cyclodextrin metal-organic framework and cannabidiol loaded on the cyclodextrin metal-organic framework; The cyclodextrin in the cyclodextrin metal organic framework is hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin; The molar ratio of cyclodextrin metal organic framework to cannabidiol in the composite is 1:(0.1-2); The coordinated metal ion in the cyclodextrin metal organic framework is Al 3+ or K + ; The mass percentage of cannabidiol in the compound is 1-20%; The preparation method of the cyclodextrin metal organic framework comprises the following steps: (1) mixing cyclodextrin and a metal compound, then ultrasonically obtaining a mixed solution, and stirring the mixed solution to obtain a pretreatment solution; (2) mixing the pretreatment solution obtained in step (1) and a cross-linking agent, and then reacting to obtain a reaction solution; (3) cooling the reaction solution obtained in step (2), and then sequentially performing solid-liquid separation, washing and drying to obtain the cyclodextrin metal organic framework; An alkaline solution is also added to the mixture in step (1), and the mass ratio of the sum of the mass of the cyclodextrin and the metal compound in step (1) to the alkaline solution is 1:(5-40).

2. The composite according to claim 1, characterized in that The crystal size of the cyclodextrin metal organic framework is 4-10 μm.

3. A method for preparing a cannabidiol complex as claimed in claim 1 or 2, characterized in that: The preparation method comprises: mixing a cyclodextrin metal organic framework and a cannabidiol solution, and then drying to obtain the cannabidiol complex; The preparation method of the cyclodextrin metal organic framework comprises the following steps: (1) mixing cyclodextrin and a metal compound, then ultrasonically obtaining a mixed solution, and stirring the mixed solution to obtain a pretreatment solution; (2) mixing the pretreatment solution obtained in step (1) and a cross-linking agent, and then reacting to obtain a reaction solution; (3) cooling the reaction solution obtained in step (2), and then sequentially performing solid-liquid separation, washing and drying to obtain the cyclodextrin metal organic framework; An alkaline solution is also added to the mixture in step (1), and the mass ratio of the sum of the mass of the cyclodextrin and the metal compound in step (1) to the alkaline solution is 1:(5-40).

4. The preparation method according to claim 3, characterized in that: The molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:(0.5-5).

5. The preparation method according to claim 4, characterized in that: The molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:(3-5).

6. The preparation method according to claim 3, characterized in that: The mass ratio of cannabidiol to solvent in the cannabidiol solution is 1:(10-50).

7. The preparation method according to claim 6, characterized in that: The solvent includes ethanol.

8. The preparation method according to claim 3, characterized in that: The mixing method includes any one of stirring treatment, microwave treatment, ultrasonic treatment or high-pressure homogenization treatment.

9. The preparation method according to claim 3, characterized in that: The drying method includes any one of freeze drying, spray drying or vacuum drying.

10. The preparation method according to claim 3, characterized in that: The molar ratio of the cyclodextrin to the metal ion in the metal compound in step (1) is 1:(0.05-0.2).

11. The preparation method according to claim 3, characterized in that: The pH of the alkaline solution in step (1) is 8-11.

12. The preparation method according to claim 11, characterized in that: The pH of the alkaline solution in step (1) is 9-10.

13. The preparation method according to claim 3, characterized in that: The ultrasonic time in step (1) is 0.2-1h.

14. The preparation method according to claim 3, characterized in that: In step (1), the alcohol additive is added to the mixed solution and then stirred.

15. The preparation method according to claim 14, characterized in that: The alcohol additive in step (1) includes methanol.

16. The preparation method according to claim 14, characterized in that: The mass ratio of the mixed solution to the alcohol additive in step (1) is 1:(0.5-5).

17. The preparation method according to claim 3, characterized in that: The stirring time in step (1) is 0.2-1h.

18. The preparation method according to claim 3, characterized in that: The cross-linking agent in step (2) includes polyethylene glycol.

19. The preparation method according to claim 18, characterized in that: The polyethylene glycol in step (2) includes any one of polyethylene glycol 4000, polyethylene glycol 8000, polyethylene glycol 12000, polyethylene glycol 16000 or polyethylene glycol 20000.

20. The preparation method according to claim 3, characterized in that: The mass ratio of the cross-linking agent to the pretreatment solution in step (2) is (0.001-0.05):

1.

21. The preparation method according to claim 3, characterized in that: The reaction time of step (2) is 0.2-1h.

22. The preparation method according to claim 3, characterized in that: The temperature of the cooling treatment in step (3) is 1-20°C.

23. The preparation method according to claim 3, characterized in that: The drying time in step (3) is 1-12 hours.

24. The preparation method according to claim 3, characterized in that: The preparation method comprises the following steps: (1) Mixing cyclodextrin and a metal compound in an alkaline solution at a mass ratio of the sum of the mass of cyclodextrin and the metal compound to the mass ratio of the alkaline solution is 1:(5-40), then ultrasonicating for 0.2-1h to obtain a mixed solution, adding methanol to the mixed solution and stirring for 0.2-1h to obtain a pretreatment solution; the pH of the alkaline solution is 8-11, the molar ratio of the cyclodextrin to the metal ion in the metal compound is 1:(0.05-0.2), the mass ratio of the mixed solution to methanol is 1:(0.5-5), and the cyclodextrin is hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin; (2) mixing the pretreatment solution obtained in step (1) and polyethylene glycol, and reacting for 0.2-1h to obtain a reaction solution, wherein the mass ratio of the polyethylene glycol to the pretreatment solution is (0.001-0.05):1; (3) cooling the reaction solution obtained in step (2) at 1-20° C., then performing solid-liquid separation and washing in sequence, and then drying for 1-12 hours to obtain the cyclodextrin metal organic framework; (4) mixing the cyclodextrin metal organic framework obtained in step (3) and the cannabidiol solution, and then drying to obtain the cannabidiol complex; the molar ratio of the cyclodextrin metal organic framework to the cannabidiol in the cannabidiol solution is 1:(0.5-5), the mass ratio of cannabidiol in the cannabidiol solution to the solvent is 1:(10-50), and the solvent includes ethanol.

25. A use of the cannabidiol complex as claimed in claim 1 or 2, characterized in that: The complex is used for preparing medicines or functional foods.

26. The use according to claim 25, characterized in that In the medicine or functional food, the mass percentage of the complex is 0.1-20%.